In the rapidly evolving landscape of nucleic acid therapeutics, ensuring the highest level of purity is paramount for both safety and efficacy. mRNA residual protein analysis service provided by CD BioGlyco is a critical component of the quality control (QC) framework for mRNA-based products. During the manufacturing of messenger RNA (mRNA), various proteins are introduced, including enzymes for in vitro transcription (IVT) like T7 RNA polymerase, inorganic pyrophosphatase, and RNase inhibitors, as well as host cell proteins (HCPs) originating from the DNA template production in organisms like Escherichia coli. Undesired residual proteins compromise the stability of the mRNA or interfere with the delivery efficiency of lipid nanoparticles (LNPs). CD BioGlyco offers sensitive and robust analytical solutions to detect, identify, and quantify these protein impurities at trace levels.
At CD BioGlyco, our mRNA residual protein analysis service is integrated into our broader Therapeutic Nucleic Acid Development Platform, specifically under the mRNA-based vaccine development and mRNA structural characterization levels. We provide a comprehensive suite of analysis services tailored to the specific needs of your mRNA modality. Our service scope includes:
We begin by optimizing the removal of the mRNA matrix and delivery lipids, which interfere with protein detection. This may involve specialized extraction buffers or precipitation techniques to isolate the protein fraction.
To detect low-abundance impurities, samples are concentrated using centrifugal filters or solid-phase extraction (SPE). We perform recovery studies to ensure that the process does not result in the loss of target proteins.
For LC-MS/MS analysis, proteins are reduced, alkylated, and digested into peptides using high-purity trypsin. This step is critical for generating the peptide maps used for protein identification.
Samples are analyzed using our state-of-the-art LC-MS/MS or ELISA. In MS-based runs, we utilize nano-flow chromatography to maximize sensitivity for trace-level contaminants.
Raw data is processed against relevant protein databases (e.g., E. coli proteome or specific enzyme sequences). We apply stringent false discovery rate (FDR) filters to ensure the accuracy of identification.
A detailed report is generated, including quantitative data, representative chromatograms/spectra, and a summary of findings. Our experts then meet with you to discuss the implications for your manufacturing process.
DoI: 10.1038/s41467-023-41354-y
Journal: Nature Communications
IF: 15.7
Published: 2023
Results: This study introduces VAX-seq, a streamlined method using long-read nanopore sequencing for comprehensive mRNA vaccine quality analysis. Unlike traditional costly and time-consuming techniques, VAX-seq simultaneously measures key attributes including sequence identity, length, integrity, poly(A) tail length, and DNA/RNA contamination across manufacturing stages. The accompanying Mana software automates quality reporting. Direct RNA sequencing further enables detection of nucleoside modifications like N1-methylpseudouridine. Compared to short-read sequencing, VAX-seq offers superior coverage of low-complexity regions (e.g., poly(A) tails) and accurate quantification of fragmented or off-target RNAs. Demonstrated on an eGFP mRNA vaccine, it provides sensitive, reproducible quality control, supporting mRNA drug development and manufacturing. This integrated approach is anticipated to become central to mRNA vaccine quality assurance.
Fig.1 mRNA vaccine production and VAX-seq workflow. (Gunter, et al., 2023)
mRNA Vaccine Development
Essential for ensuring the safety of prophylactic and therapeutic vaccines by identifying residual enzymes and host proteins that might trigger off-target immune responses or affect stability.
Gene Therapy Research
Used to characterize mRNA used in ex vivo cell engineering or in vivo gene replacement, ensuring that the mRNA product is highly purified and meets your standards.
Process Optimization (CMC)
Provides critical data during the scale-up of mRNA production, allowing developers to compare the efficiency of different purification resins or ultrafiltration steps in removing protein impurities.
Unmatched Sensitivity
Our high-resolution MS and optimized ELISA protocols allow for the detection of residual proteins at concentrations as low as 1-10 ppm, ensuring the highest possible product safety.
Customized Assay Development
CD BioGlyco offers tailored method development to address specific process enzymes or complex lipid nanoparticle matrices that traditional kits might miss.
Expert Data Interpretation
Our team of PhD-level scientists provides more than just raw data; we offer deep insights into the origin and potential impact of detected impurities on your therapeutic's performance.
Rapid Turnaround Times
By leveraging automated platforms and streamlined workflows, we deliver comprehensive results quickly, helping you maintain your project timelines.
"The level of detail in the residual protein report from CD BioGlyco was exceptional. We were able to identify a specific host protein that was causing stability issues in our LNP formulation."
– A.F., Biotech Company
"We struggled with matrix interference in our mRNA samples for months. CD BioGlyco's team developed a custom extraction protocol that finally gave us the sensitive HCP data we needed."
– B.T., Pharmaceutical Research Institute
"The team at CD BioGlyco feels like an extension of our own lab. Their residual protein analysis is a staple in our vaccine development workflow."
– A.T., RNA Therapy Center
CD BioGlyco provides a sophisticated and reliable mRNA residual protein analysis service that is vital for the development of safe and effective mRNA vaccines and therapeutics. By combining cutting-edge MS with sensitive immunoassays, we deliver the precision required to meet industry standards. Please feel free to contact us for more information and to discuss your project.
Reference
